Document Detail

Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost.
MedLine Citation:
PMID:  1717784     Owner:  NLM     Status:  MEDLINE    
Thrombolytic effects of tissue-type plasminogen activator (t-PA) are limited by in vivo platelet activation and dynamic coronary vasoconstriction. To examine if the concurrent administration of a fibrin(ogen)-degradation product, pentapeptide 6A (Ala-Arg-Pro-Ala-Lys) with t-PA would improve the thrombolytic effects of t-PA, dogs with electrically induced coronary thrombus were given t-PA alone or with peptide 6A. In dogs given t-PA alone (0.75 mg/kg over 20 min), coronary blood flow was restored in 69% of animals (9 of 13 dogs), with a mean time to reflow of 21 +/- 10 min and duration of reflow of 35 +/- 18 min. Reocclusion occurred in 77% of dogs (7 of 9 dogs). With concurrent administration of peptide 6A (200 mumol), coronary venous 6-keto-PGF1 alpha concentrations increased from 221 +/- 71 to 422 +/- 161 pg/ml (p less than 0.05), but not with t-PA given alone. Coronary blood flow was restored in 7 of 11 dogs (reperfusion rate 64%), with mean time to reflow of 17 +/- 7 min and duration of reflow of 35 +/- 15 min. The coronary reocclusion rate was 86%. All these indices of thrombolysis were similar to those in dogs given t-PA alone. In ex vivo experiments, we also demonstrated release of endothelium-derived relaxing factor from canine coronary artery rings in response to peptide 6A. To further examine the role of prostacyclin (PGI2) in thrombolytic response to t-PA, eight other dogs were given t-PA with a PGI2 analog iloprost (100 ng/kg/min for 40 min).(ABSTRACT TRUNCATED AT 250 WORDS)
W W Nichols; F A Nicolini; T G Saldeen; J L Mehta
Related Documents :
22342944 - In vivo assessment of ergonovine-induced coronary artery spasm by 64-slice multislice c...
518794 - Acute effect of fentanyl on haemodynamics and myocardial carbohydrate utilization and p...
71034 - relationship between cardiac arrhythmia and elevated concentrations of free fatty acids...
3655154 - Altered response of reperfused myocardium to repeated coronary occlusion in dogs.
24566464 - Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a ...
24251454 - Acute decompensated heart failure update.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991 Aug 
Date Detail:
Created Date:  1991-11-08     Completed Date:  1991-11-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  231-6     Citation Subset:  IM    
University of Florida College of Medicine, Department of Medicine, Gainesville.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Circulation / drug effects
Coronary Thrombosis / drug therapy*
Drug Therapy, Combination
Epoprostenol / metabolism
Hemodynamics / drug effects
Iloprost / therapeutic use*
Nitric Oxide / metabolism
Tissue Plasminogen Activator / therapeutic use*
Reg. No./Substance:
10102-43-9/Nitric Oxide; 35121-78-9/Epoprostenol; 78919-13-8/Iloprost; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interaction of taurine with methionine: inhibition of myocardial phospholipid methyltransferase.
Next Document:  Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inh...